On July 14, 2021 Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, reported the closing of a $65 million financing (Press release, Ribon Therapeutics, JUL 14, 2021, View Source [SID1234584833]). The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group. Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to have this terrific group of new investors join our strong group of existing investors to enable Ribon to develop novel precision drugs targeting stress support pathways," said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. "The additional capital will enable the advancement of our lead programs, RBN-2397 in cancer and RBN-3143 in inflammation, through key clinical milestones as well as support additional drug discovery and validation from our proprietary BEACON+ platform. We look forward to realizing our mission to bring novel small molecule therapeutics to patients and families in need."
"Ribon is pioneering the development of first-in-class precision development candidates targeting stress support pathways in cancer and inflammation and has made notable progress advancing its lead candidates," said Cameron Wheeler, Ph.D., Partner, Deerfield Management and Board Director for Ribon Therapeutics. "This funding represents a commitment to the compelling science that marks the foundation of Ribon and we look forward to working with management on continued clinical, preclinical and platform discovery execution."